Literature DB >> 34580061

ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression.

Cuicui Liu1,2, Jiankun Qiang1, Qiaodan Deng1, Jie Xia1, Lu Deng3, Lei Zhou4, Dong Wang5, Xueyan He1, Ying Liu6, Botao Zhao6, Jinhui Lv7, Zuoren Yu7, Qun-Ying Lei1, Zhi-Ming Shao8,9, Xiao-Yong Zhang10,11, Lixing Zhang8, Suling Liu8,2.   

Abstract

Tumor-initiating cells (TIC) are associated with tumor initiation, growth, metastasis, and recurrence. Aldehyde dehydrogenase 1A1 (ALDH1A1) is a TIC marker in many cancers, including breast cancer. However, the molecular mechanisms underlying ALDH1A1 functions in solid tumors remain largely unknown. Here we demonstrate that ALDH1A1 enzymatic activity facilitates breast tumor growth. Mechanistically, ALDH1A1 decreased the intracellular pH in breast cancer cells to promote phosphorylation of TAK1, activate NFκB signaling, and increase the secretion of GM-CSF, which led to myeloid-derived suppressor cell expansion and immunosuppression. Furthermore, the ALDH1A1 inhibitor disulfiram and chemotherapeutic agent gemcitabine cooperatively inhibited breast tumor growth and tumorigenesis by purging ALDH+ TICs and activating T-cell immunity. These findings elucidate how active ALDH1A1 modulates the immune system to promote tumor development, highlighting new therapeutic strategies for malignant breast cancer. SIGNIFICANCE: ALDH1A1 enzyme activity induces MDSC expansion and triggers a procancer immune microenvironment to facilitate breast cancer progression, providing a novel therapeutic vulnerability in this disease. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34580061     DOI: 10.1158/0008-5472.CAN-21-1337

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.

Authors:  Azam Bozorgi; Maryam Bozorgi; Mozafar Khazaei
Journal:  Cell Oncol (Dordr)       Date:  2022-08-09       Impact factor: 7.051

Review 2.  Research progress in breast cancer stem cells: characterization and future perspectives.

Authors:  Xiao-Dong Mao; Xiao Wei; Tao Xu; Tai-Ping Li; Kang-Sheng Liu
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

3.  [ALDH3B1 expression is correlated with histopathology and long-term prognosis of gastric cancer].

Authors:  Q Li; Q Qiu; L Zhang; X Zhang; Y Wang; Z Geng; S Ge; L Zuo; X Song; J Li; J Hu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

Review 4.  Drug-Tolerant Persister Cells in Cancer Therapy Resistance.

Authors:  Pavan Kumar Dhanyamraju; Todd D Schell; Shantu Amin; Gavin P Robertson
Journal:  Cancer Res       Date:  2022-07-18       Impact factor: 13.312

Review 5.  ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism.

Authors:  Hanxun Yue; Zenan Hu; Rui Hu; Zeying Guo; Ya Zheng; Yuping Wang; Yongning Zhou
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

6.  Bioinformatics and Experimental Analysis of the Prognostic and Predictive Value of the CHPF Gene on Breast Cancer.

Authors:  Wan-Wan Li; Bin Liu; Shu-Qing Dong; Shi-Qing He; Yu-Ying Liu; Si-Yu Wei; Jing-Yi Mou; Jia-Xin Zhang; Zhao Liu
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

Review 7.  Comparison Efficacy and Safety of Gemcitabine plus Cisplatin and 5-Fluorouracil plus Cisplatin for Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis and Systematic Review.

Authors:  Le Yan; Hanxue Zheng; Bi Ren; Huiping Zhang; Haocheng Gou; Lintong Dai
Journal:  J Oncol       Date:  2022-07-16       Impact factor: 4.501

Review 8.  Disulfiram in glioma: Literature review of drug repurposing.

Authors:  Shiyu Zhong; Xudong Zhang; Kunhang Li; Guojun Liu; Lishuai Li; Shanwei Tao; Bowen Zheng; Weichen Sheng; Ziyin Ye; Qichen Xing; Qingqing Zhai; Lijie Ren; Ying Wu; Yijun Bao
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.